Amol Akhade

Amol Akhade: Oral SERDs and PROTACs in ER+/HER2– Metastatic Breast Cancer – Trial Landscape Update

Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:

“Oral SERDs and PROTACs in ER+/HER2– Metastatic Breast Cancer: Trial Landscape Update

The therapeutic race is heating up in ER+/HER2– mBC. Here’s a quick snapshot of where key agents stand:

FDA-Approved:

Elacestrant (Orserdu): Approved Jan 2023 for ESR1-mut mBC (EMERALD trial)

In Trials:

Camizestrant (SERENA-6): PFS benefit in early-switch strategy (ESR1+ ctDNA-guided) Imlunestrant (EMBER-3), Giredestrant (acelERA), Palazestrant (OPERA-1): Still ongoing

Withdrawals:

Vepdegestrant (ARV-471): Despite PFS signal in ESR1-mut group, both Phase 3 trials (VERITAC-3 and atirmociclib combo) were withdrawn in Jan and May 2025 by Arvinas/Pfizer as part of pipeline reprioritization

Emerging PROTACs:

AC0682 (Accutar): Now in Phase 1 ZD12: Potent preclinical ERα degrader

One Slide. All Trials. All Statuses.”

SERDs and PROTACs

Further Reading: 

Elacestrant (Orserdu): Uses in Cancer: Side effects: Dosage: Expectations, and More

Elacestrant: What patients need to know?

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

AC0682 (Accutar) Amol Akhade Breast Cancer Camizestrant (SERENA-6) cancer Elacestrant (Orserdu) ER+/HER2- metastatic breast cancer metastatic breast cancer OncoDaily Oncology SERDs and PROTACs Vepdegestrant (ARV-471)